UNCPM 22322 - Adaption of the Transition of Care Model for Post-Discharge HIV-NCD Care in Lilongwe, Malawi - MLATHO
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · Apr 14, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The UNCPM 22322 trial, also known as the MLATHO study, is looking at ways to improve care for adults in Malawi who are living with HIV and other long-term health conditions, known as noncommunicable diseases (NCDs). The researchers want to adapt a care model that has been successful in the United States to help these patients after they leave the hospital, ensuring they receive the right support to manage their health.
To be eligible for this study, participants must be at least 18 years old, living with HIV, and have been admitted to the hospital for internal medicine with a heart-related condition or another serious health issue related to HIV. The trial is not currently recruiting participants, but when it begins, those who take part can expect to receive tailored support that aims to improve their health outcomes after discharge. It's important to note that only patients living within the urban area of Lilongwe will be able to participate in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • living with HIV
- • admitted to internal medicine
- • has at least a cardiometabolic NCO as the primary or secondary reason for admission based on the HIV inpatient consultation
- Exclusion Criteria:
- • patients living beyond Lilongwe urban
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lilongwe, , Malawi
Patients applied
Trial Officials
Cecilia Kanyama, MBBS
Principal Investigator
University of North Carolina at Chapel Hill (Project Malawi)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported